SCHEMBL20928645

SCHEMBL20928645

O=C(O)c1nnccc1S

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HCAR2 Q8TDS4 2/20 0.39
KDM4E B2RXH2 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
BLM P54132 1/20 0.36
AGER Q15109 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HDAC8 Q9BY41 1/20 0.35
CYP1A2 P05177 3/20 0.34
ASPH Q12797 1/20 0.34
KDM8 Q8N371 1/20 0.34
CYP2C9 P11712 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
NAPRT Q6XQN6 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29008885 0.76 KDM4E (0.44) MAPTALDH1A1SMN1; SMN2HCAR2KDM4E
SCHEMBL5769273 0.76 KDM4E (0.52) MAPTALDH1A1SMN1; SMN2HCAR2KDM4E
SCHEMBL352338 0.76 HCAR2 (0.40) MAPTALDH1A1SMN1; SMN2HCAR2KDM4E
SCHEMBL354481 0.74 HCAR2 (0.39) MAPTALDH1A1SMN1; SMN2HCAR2KDM4E
SCHEMBL5270728 0.74 HCAR2 (0.39) MAPTALDH1A1SMN1; SMN2HCAR2KDM4E
SCHEMBL5120006 0.74 KDM4E (0.44) MAPTALDH1A1SMN1; SMN2HCAR2KDM4E
SCHEMBL31445147 0.74 KMO (0.36) MAPTALDH1A1HCAR2KDM4EL3MBTL1
SCHEMBL11846126 0.71 MAPT (0.38) MAPTALDH1A1SMN1; SMN2HCAR2KDM4E
SCHEMBL20928637 0.70 MAPT (0.31) MAPTALDH1A1SMN1; SMN2HCAR2HDAC8
SCHEMBL20928648 0.70 KDM5B (0.45) MAPTALDH1A1SMN1; SMN2HCAR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11022880-B2 Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound TOKYO OHKA KOGYO CO., LTD. (JP) 2021-06-01 US disclosed
US-20190121233-A1 CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PATTERNED RESIST FILM, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, METHOD OF MANUFACTURING PLATED ARTICLE, AND MERCAPTO COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190121233-A1 CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PATTERNED RESIST FILM, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, METHOD OF MANUFACTURING PLATED ARTICLE, AND MERCAPTO COMPOUND CUTA, POLR1C, ASIC1 MAPT 1711/4885ALDH1A1 639/4885SMN1; SMN2 3672/4885
US-11022880-B2 Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound CUTA, POLR1C, ASIC1 MAPT 1711/4885ALDH1A1 639/4885SMN1; SMN2 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.